Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by J.P. Marvel Investment Advisors LLC

J.P. Marvel Investment Advisors LLC cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 4.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 37,604 shares of the medical research company’s stock after selling 1,827 shares during the period. Charles River Laboratories International makes up 1.1% of J.P. Marvel Investment Advisors LLC’s holdings, making the stock its 24th biggest holding. J.P. Marvel Investment Advisors LLC owned approximately 0.07% of Charles River Laboratories International worth $6,942,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Versant Capital Management Inc increased its position in shares of Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 150 shares during the last quarter. Assetmark Inc. increased its position in shares of Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 173 shares during the last quarter. Pinnacle Bancorp Inc. increased its position in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 65 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Charles River Laboratories International during the third quarter valued at about $59,000. Finally, ORG Wealth Partners LLC acquired a new stake in shares of Charles River Laboratories International during the fourth quarter valued at about $56,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CRL has been the subject of a number of research reports. William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. The Goldman Sachs Group dropped their price objective on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Morgan Stanley dropped their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a report on Wednesday, February 5th. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Finally, UBS Group restated a “neutral” rating and issued a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $200.79.

Charles River Laboratories International Stock Down 0.7 %

Shares of NYSE:CRL opened at $152.07 on Friday. The company has a market capitalization of $7.78 billion, a PE ratio of 19.03, a P/E/G ratio of 6.47 and a beta of 1.37. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $275.00. The firm has a 50 day simple moving average of $176.43 and a 200-day simple moving average of $190.73.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).